{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '9.', 'Reporting promptly, all changes in the research activity and all unanticipated', 'problems involving risks to human subjects or others, to the appropriate individuals', '(e.g., coordinating investigator, institution director) and/or directly to the ethics', 'committees and AbbVie.', '10.', 'Following the protocol and not making any changes in the research without ethics', 'committee approval, except where necessary to eliminate apparent immediate', 'hazards to human subjects.', '118']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix B.', 'List of Protocol Signatories', 'Name', 'Title', 'Functional Area', 'Clinical', 'Clinical', 'Pharmacokinetics', 'Clinical Drug Supply Management', 'Statistics', 'Bioanalysis', '119']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix C.', 'Study Activities', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatmentb', 'PTFU', '(OS)', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day 1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Location', 'Clinic Visit', 'X', 'X', 'X', 'X', 'X', 'X', 'Phone Contact', 'X', 'X', 'X', 'Safety', 'Informed Consent', 'X', 'Assessments', 'Inclusion/Exclusion', 'X', 'Criteria', 'Medical and', 'X', 'Surgical History', 'including', 'Malignancy', 'History8', 'Physical', 'X', 'X', 'X', 'X', 'X', 'examination', 'Vital Signs\u00b9', 'X', 'X', 'X', 'X', 'X', 'Hematology and', 'X', 'Xk', 'X', 'X', 'X', 'Serum Chemistry', 'Coagulation Tests\u00b9', 'X', 'Xk', 'X', 'X', '120']\n\n###\n\n", "completion": "END"}